Biokine Therapeutics Ltd.

Kyoto University

Shin-etsu Chemical Co., Ltd.

Takeda Pharmaceutical Company Limited

Other

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Takeda Chemical Industries, Inc.

Chugai Seiyaku Kabushiki Kaisha

Hadasit Medical Research Services and Development Ltd.

Seikagaku Kogyo Co. Ltd.

Arigen Pharmaceuticals, Inc.

Seikagaku Kogyo K.k.

Seikagaku Kogyo Kabushiki Kaisha

Nobutaka Fujii

Naoki Yamamoto

Shinya Oishi

Akira Hori

Hirokazu Tamamura

Akiyoshi Matsumoto

Michinori Waki

Kenji Tomita

Haruaki Yajima

Amnon Peled

Joseph Stork Smith

Louis H Miller

Ayumu Niida

Hideaki Kakeya

Bruno Pouvelle

Tatsuhiko Honguu

Artur Scherf

Pierre Buffet

Soichi Kojima

Benoit Gamain

Dror I Baruch

Mitsuko Hara

Christine Scheidig

Akira Hattori

Jurg Gysin

Ryuichiro Doi

Yasuaki Takasu

Gilberto M Guterres

Shinya Kiyama

Hirokazu; Tamamura

The present invention provides novel uses for CXCR4 antagonists, including specifically peptides of the T-140 family, in the treatment of skin burns and other injuries. The invention further provides methods for increasing epithelialization in a subject in need thereof, and for preventing or inhibiting fibrosis and excessive scar formation, using peptide inhibitors of the T-140 family as well as other CXCR4 antagonists.

CXCR4 antagonists for wound healing and re-epithelialization

The present invention provides a compound represented by the following formula (I) or a physiologically acceptable salt thereof, and use thereof for the prophylaxis or treatment of TGF-&#x3b2;-related diseases:   

TGF-&#x3b2; signal transduction inhibitor

The present invention provides a metastin derivative represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a pharmaceutical composition containing it. The metastin derivative or a salt thereof is superior in blood stability, and has a cancer metastasis suppressive action or cancer growth suppressive action.

Metastin derivative and use thereof

The present invention provides novel polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like), and methods of using same in the treatment of HIV.

Polypeptide anti-HIV agent containing the same

Therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt are described. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.

CXCR4 antagonist and use thereof

The present invention provides a compound represented by the following formula (1); wherein

Compound having GPR54 agonistic activity

Peptides, their amides, esters or salts, which have CXCR4 antagonistic action, have therapeutic effects for cancer and chronic rheumatoid arthritis.

The present invention relates to a polypeptide represented by the formula:A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit-Cys-A7&#x2003;&#x2003;(I)(wherein A1 represents a hydrogen atom or an arginine, lysine, ornithine, citrulline, alanine residue, etc.; A2 represents an aromatic amino acid residue; A3, A4 and A6 represent an arginine, lysine, ornithine, citrulline or alanine residue, A5 represents a tyrosine, phenylalanine, alanine, naphthylalanine or citrulline residue; A7 represents a lysine or arginine residue in which a carboxyl group may be amidated; X represents a D-ornithyl-proline, prolyl-D-ornithine, D-lysyl-proline residue, etc.; provided that either of A1, A3, A4, A5, A6 and A7 is an alanine residue, etc., or X is citrulline, etc.) or a salt thereof.

Polypeptides having anti-HIV activity and compositions comprising same

The present invention provides an anti-coronavirus agent including as an active ingredient as exemplified by nelfinavir and salts thereof, an anti-SARS agent including the anti-coronavirus agent, and a method of treating SARS using the anti-SARS agent.

Anti-coronavirus drug

The present invention provides preventive and/or therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.

Cxcr4 antagonist and use thereof

Polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like).

The present invention relates to the discovery of a var gene and corresponding protein that modulates adhesion of parasitized red blood cells to chondroitin sulfate A. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.

Identification of the domain of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) that mediates adhesion to chondroitin sulfate A

The invention relates to metastin derivatives represented by the formula: X-AA -AA -AA -AA -Z (I), or a salt thereof, or a pro-drug thereof, which have cancer metastatis suppressing activity and cancer proliferation suppressing activity. The invention also relates to the use of these derivatives as drugs for preventing or treating cancers.

Metastin derivatives and their use

Compounds with antitumor activity

A novel polypeptide sequence having the formula ##STR1## in which A.sub.1 is a hydrogen or at least one and no more than two amino acids selected from the group consisting of lysine and arginine,

Pharmaceutical compositions of lipopolysaccharide-binding polypeptides

Growing community of inventors

Shiga, Japan

Nobutaka Fujii